Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
AS

NASDAQ · ASLN

ASLAN Pharmaceuticals Limited

Healthcare · Biotechnology

$0.60

Down-$0.10 (-14.27%)

Updated Sep 11, 2026, 9:19 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
777.12M
P/E ratio
-0.06
Dividend yield
0.00%
52-week range
— – —
Volume
769.82K
Avg. volume
102.49K

Price performance

ASLN price history

1M range · 0 trading sessions · Daily adjusted prices

ASLN does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ASLN news

The latest Smart Investors Daily articles mentioning ASLN.

Stock researchCompany · Overview

ASLN research

Overview

Company profile and research snapshot.

Company profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ASLN recent ratings
DateFirmRatingTarget
May 3, 2024HC Wainwright & Co.Buy—
Apr 23, 2024HC Wainwright & Co.Buy—
Apr 15, 2024HC Wainwright & Co.Buy—
Mar 18, 2024HC Wainwright & Co.Buy—
Mar 13, 2024Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Jun 14, 2024

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares.

GlobeNewswire Inc. · May 21, 2024

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

SAN MATEO, Calif. and SINGAPORE, May 21, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the late-breaking poster presentation of translational data from head-to-head studies of eblasakimab and dupilumab in human healthy and COPD-derived lung tissue models at the American Thoracic Society (ATS) International Conference 2024 in San Diego, California.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By